Category Archives: Public Policy

Latest From Public Policy

Myriad Genetics’ actions justify a ban on gene patents?

Virus

The following information was provided by Myriad’s General Counsel during his presentation on the subject during a recent BIO IP conference: In order to develop and then ensure the widest possible distribution of the Myriad BRCA diagnostic test, Myriad needed to make the initial discovery, educate the medical community on the values of personalized medicine (the BRCA test), convince insurance companies to cover the test, and educate the patient community.  All of these activities took Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Banning Gene Patents Will Promote Innovation?

Hampton Roads Partnership

Abolishing gene patents will deter, not promote, innovation, as the patent eligibility of isolated DNA molecules provides incentives necessary for development of life-enhancing diagnostics and therapeutics. R&D to identify genes, their sequences, genetic variations, and their disease  correlation is very costly. Claims like those of the patents at issue in the Myriad Genetics lawsuit have been a key foundation supporting the massive investment of time and capital that is necessary to bring life-enhancing DNA-based diagnostics Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Celebrating 30 Years of Biotechnology Innovation: From Diamond v. Chakrabarty to Today

Kappos-200

David Kappos, Under Secretary of Commerce for Intellectual Property and Director of the U.S. Patent and Trademark Office (USPTO), provided opening remarks at an event entitled, Celebrating 30 years of Biotechnology Innovation: From Diamond v. Chakrabarty to Today during the 2011 BIO International Convention. The forum, co-sponsored by the US Patent and Trademark Office, The Biotechnology Industry Organization and the Biojudiciary Project, celebrated the 30th anniversary of the issuance of the patent from the Supreme Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

USTR: TPP to have High IP Standards to “Stand Alongside other Treaty Agreements in the Area”

Stan McCoy, Assisant U.S. Trade Representative for Intellectual Property and Innovation, spoke at BIO’s 2011 Convention session titled The Trans-Pacific Partnership and the Importance of Intellectual Property Rights: Attracting Investment in Biotechnology.  The session covered the ongoing treaty negotiations and the relevance of different IP provisions to the biotechnology industry.  Issues of particular importance to the biotechnology industry yet to be revelead to the public include language tabled for data protection and patent linkage.  While USTR specific language is not available, Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Patents in the U.S. Supreme Court

joseph a

A special session at the 2011 BIO International Convention takes a fascinating look at the underlying factors involved in the U.S. Supreme Court hearing patent cases. The Supreme Court has been accepting patent cases at a higher rate than ever before, with three major patent appeals reviewed this past term alone.  And the Court seems poised to accept several more in the coming year. According to the session moderator, Chief Judge (Ret.) Paul Michel from Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , , , , ,